Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H28N2O5S2.ClH |
Molecular Weight | 513.07 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(CC(O)=O)C2=O)C3=CC=CS3
InChI
InChIKey=XDDQNOKKZKHBIX-ASBZXGSUSA-N
InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2851680Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11686312 | https://www.ncbi.nlm.nih.gov/pubmed/19932971 |
https://www.drugs.com/international/acecol.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2851680
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11686312 | https://www.ncbi.nlm.nih.gov/pubmed/19932971 |
https://www.drugs.com/international/acecol.html
Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2851680 |
3.6 nM [IC50] | ||
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2851680 |
3.6 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Acecol Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11686312
A tablet containing 2 mg of temocapril hydrochloride was administered once a day in the morning, and the monitoring term was for 16 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2851680
A force of 1.0 g was applied, and the strips were allowed to equilibrate for 90 min. Aortic strips were exposed to 30 nM of angiotensin I (AI), which produced contractions approximately equal to 90% of the maximum response. After three successive contractions of equal size had been obtained, test drugs (CS-622 diacid) was added to the bath. Contractile responses to AI in the presence of a test drug were compared with control responses before the drug was added. The concentration of the drug was increased in a cumulative manner by a ratio of 3 at a 10 min interval to construct a concentration
inhibition curve. The IC50 value was determined as the concentration inhibiting by 50% the response to AI
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
110221-44-8
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
443873
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110627
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
DTXSID7046914
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
SUB04716MIG
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
FF-33
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
C99556
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
C055603
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
DBSALT000171
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
m10549
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
8G820I95VP
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY | |||
|
100000084791
Created by
admin on Fri Dec 15 15:38:27 GMT 2023 , Edited by admin on Fri Dec 15 15:38:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD